Glenmark Pharmaceuticals to open new translational research center in LausanneMonday, 12 March 2018
Based at the Biopôle campus in Lausanne, the facility will enhance the group’s current capabilities in translational research.
Global pharmaceutical company Glenmark Pharmaceuticals will enhance its capabilities in translational research by setting up a new discovery center at the Biopôle campus in Lausanne. Present in Switzerland since 2004, the company employs approximately 160 people at its R&D center for biologics in the canton of Neuchâtel. Around 20% of current employees will be housed in the new facility, while Glenmark will continue to invest in its existing Swiss site.
Biopôle: an inspiring environment, a vibrant community
Spread across 80,000 m2, Biopôle is the largest business park in Switzerland dedicated to life sciences. It brings together partners developing innovative solutions in the fields of oncology, immunology and personalized medicine.
"The Biopôle is one of the most vibrant ecosystems for life sciences innovation in Europe. This expansion opens a universe of opportunity to foster our innovation capabilities by collaborating with the world-class research centers, academic groups and hospitals in the Lausanne vicinity. At the same time, Glenmark's long-term commitment to our development center in the region of Neuchâtel will remain a key priority," said Dr. Kurt Stoeckli, President and Chief Scientific Officer at Glenmark Pharmaceuticals, in a press release.